French pharma major Sanofi (Euronext: SAN) is taking aim at Novo Nordisk’s (NOV: N) Tresiba (insulin degludec) with two batches of data comparing its newest insulin glargine product Toujeo with Novo’s long-acting insulin option.
Toujeo, a more concentrated version of the company’s insulin workhorse Lantus (insulin glargine), was approved by the US FDA in February 2015.
Tresiba, a new kind of ultra-long acting insulin for type 1 or type 2 diabetes, was approved in the USA six months later.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze